Severe asthma manifests as airway remodeling and irreversible airway obstruction, in part because of the proliferation and migration of human airway smooth muscle (HASM) cells. We previously reported that cyclic adenosine monophosphate-mobilizing agents, including b 2 -adrenergic receptor (b 2 AR) agonists, which are mainstay of asthma therapy, and prostaglandin E2 (PGE2), inhibit the migration of HASM cells, although the mechanism for this migration remains unknown. Vasodilator-stimulated phosphoprotein (VASP), an anticapping protein, modulates the formation of actin stress fibers during cell motility, and is negatively regulated by protein kinase A (PKA)-specific inhibitory phosphorylation at serine 157 (Ser157). Here, we show that treatment with b 2 AR agonists and PGE2 induces the PKA-dependent phosphorylation of VASP and inhibits the migration of HASM cells. The stable expression of PKA inhibitory peptide and the small interfering (si) RNA-induced depletion of VASP abolish the inhibitory effects of albuterol and PGE2 on the migration of HASM cells. Importantly, prolonged treatment with albuterol prevents the agonist-induced phosphorylation of VASP at Ser157, and reverses the inhibitory effects of albuterol and formoterol, but not PGE2, on the basal and PDGF-induced migration of HASM cells. Collectively, our data demonstrate that b 2 AR agonists selectively inhibit the migration of HASM cells via a b 2 AR/PKA/ VASP signaling pathway, and that prolonged treatment with albuterol abolishes the inhibitory effect of b-agonists on the phosphorylation of VASP and migration of HASM cells because of b 2 AR desensitization.
Human airway smooth muscle (HASM) hyperplasia and remodeling are characteristic features of airways that contribute to their irreversible obstruction in patients with severe asthma. Accumulating evidence suggests that cell migration contributes to airway smooth muscle hyperplasia and remodeling (1, 2) . Recently, the migration of airway smooth muscle (ASM) cells toward the epithelium and lumen of the airway was reported as a potential contributor to the increased smooth muscle mass in patients with asthma (3, 4) . Further, cell-culture studies show that mitogens and inflammatory mediators involved in asthma pathogenesis and pharmacological agents in current used for the treatment of asthma modulate the migration of ASM cells (1, 5, 6) . Taken together, these studies suggest that the migration of ASM cells contributes to ASM cell hyperplasia under asthmarelated conditions (1) . Although the role of HASM hyperplasia in asthma is well established, the molecular mechanisms regulating the migration of HASM cells under asthma-related conditions are poorly understood (1) .
Evidence demonstrates that cyclic adenosine monophosphate (cAMP)-inducing agents, including the long-acting b 2 -adrenergic receptor (b 2 AR) agonist formoterol, inhibit the agonist-dependent migration of ASM cells (5, 7) . We previously reported that the cAMP-inducing agents salmeterol, cilomolast, and prostaglandin E2 (PGE2) attenuate the migration of HASM cells (6) and induce actin depolimerization in HASM cells (8) . However, the mechanisms by which b 2 AR agonists modulate the actin cytoskeleton and inhibit cell migration remain unknown.
Cell migration requires actin cytoskeleton remodeling, including the disassembly of actin stress fibers and the formation of actin branching at the lamellipodia protrusion at the leading edge of migrating ASM cells. Vasodilator-stimulated phosphoprotein (VASP) belongs to a conserved family of actinregulatory proteins that regulate actin stress fiber assembly during cell migration (9) . VASP facilitates the assembly of the actin filaments by serving as an anticapping protein (9) . Agents that elevate cellular concentrations of cAMP and cyclic guanosine monophosphate promote the inhibitory phosphorylation of VASP and attenuate the anticapping activity of VASP (9) . The activity of VASP is negatively regulated by the inhibitory phosphorylation of serine 157 (Ser157) by protein kinase A (PKA)
CLINICAL RELEVANCE
Understanding the cellular and molecular mechanisms of human airway smooth muscle (HASM) remodeling is critically important, not only for advancing our knowledge about disease pathobiology but also in terms of indentifying novel molecular targets for therapeutic intervention. This study identifies a mechanism for the inhibitory effects of b 2 -adrenergic receptor (b 2 AR) agonists on the migration of HASM cells. We found that the b 2 AR agonist-induced activation of protein kinase A modulates the phosphorylation of vasodilatorstimulated phosphoprotein, which inhibits the migration of HASM cells. Furthermore, we found that the prolonged treatment of HASM cells with b2AR agonists desensitizes the airways to further treatment with the b2AR agonist. Our data suggest that the prolonged use of b2AR agonists in asthma as a single therapy may promote the development of tolerance to b2AR agonists and the migration of airway smooth muscle cells. (9) . Although the importance of protein kinase A in cell migration is supported by several reports, published data indicate that PKA may serve to either promote or inhibit cell motility (10) (11) (12) , suggesting that the role of PKA in cell migration is highly cell type-dependent and context-dependent. b 2 AR agonists modulate the activity of PKA via the production of cAMP, but the role of PKA/VASP signaling in the b 2 AR agonistdependent migration of HASM cells remains unclear.
In this study, we demonstrate that b 2 AR agonists modulate the migration of HASM cells through a b 2 AR/PKA/VASP signaling pathway. We also show that the prolonged exposure of HASM cells to albuterol abrogates the PKA-specific phosphorylation of VASP, and prevents the b 2 AR agonist-dependent inhibition of HASM cell migration, suggesting the potential clinical relevance of our findings.
MATERIALS AND METHODS
Cell Culture HASM cells were dissociated from human tracheas obtained from human lung transplant donors, in accordance with procedures approved by the Committee on Studies Involving Human Beings at the University of Pennsylvania, as described previously (13) . Cells were cultured in Ham's F12 media (Life Technologies, Grand Island, NY), supplemented with 10% FBS (HyClone Laboratories, Logan, UT), 100 U/ml penicillin, and 0.1 mg/ml streptomycin. Before the experiments, HASM cells were maintained for 48 hours in serum-free Ham's F12 media, supplemented with 0.1% BSA.
Immunoblot Analysis
Growth-arrested cells were transfected with siRNA VASP or control small interfering (si) RNA, or treated with different concentrations of racemic, (R)-albuterol (where "R" stands for rectus) or (S)-albuterol (where "S" stands for sinistre), formoterol, PGE2, or propranolol in the presence or absence of preincubation with albuterol, followed by immunoblot analysis with anti-phospho VASP Ser157 or anti-VASP antibodies (Cell Signaling Technology, Inc., Danvers, MA).
Immunocytochemical Analysis
Cells growth-arrested for 48 hours were incubated with 0.01, 0.1, 1, or 10 mM formoterol or diluent for 5, 15, or 30 minutes, or with 10 mM (R)-albuterol, (S)-albuterol, or diluent for 5, 15, and 30 minutes, followed by immunocytochemical analysis with anti-phospho VASP Ser157 antibody, as previously described (14) . A detailed explanation of the technique is provided in Figure E1 in the online supplement.
Transient Transfection
Cells were transfected with 100 or 250 nM siRNA VASP or control siGLO RISC-Free (GLO) siRNA for 48 hours with RNAiFect transfection reagent (Qiagen, Valencia, CA), according to the manufacturer's protocol, as described elsewhere (15) . The siRNA-induced depletion of VASP was confirmed by immunoblot analysis with anti-VASP antibody.
Cell Migration Assay
Cell migration was examined using a Boyden chamber apparatus, as we described previously (6, 16) . Briefly, HASM cells were growth-arrested for 48 hours, transfected with siRNA VASP or control siRNA GLO, or incubated with albuterol. HASM cells were then briefly trypsinized by 0.05% trypsin/0.53 mM EDTA, centrifuged at 900 rpm for 10 minutes, and resuspended in serum-free media supplemented with BSA. Cells (5 3 10 4 ) were then placed into the upper wells of the Boyden chamber, fitted with an 8-mm pore membrane coated with Vitrogen (Advanced BioMatrix, San Diego, CA) (100 mg/ml). Agonists or vehicle in serumfree media supplemented with BSA were added to the lower chambers. Cells in the Boyden chamber were incubated for 4 hours at 37 8 C in a 5% CO 2 incubator. Nonmigrated cells were scraped off. The membrane was fixed with methanol, stained with a Hemacolor stain set (EM Industries, Inc., Gibbstown, NJ), and scanned. Cell migration was analyzed using the Gel-Pro analyzer program (Media Cybernetics, Silver Spring, MD).
Statistical Analysis
Data points from individual assays represent mean values 6 SE. Statistically significant differences among groups were assessed according to ANOVA (Bonferroni-Dunn test), with values of P , 0.05 considered sufficient to reject the null hypothesis for all analyses. All experiments were designed with matched control conditions within each experiment, to enable statistical comparisons as paired samples. All experiments were performed with a minimum of three different HASM cell cultures.
RESULTS

Short-Term Treatment with b 2 AR Agonists and PGE2 Promotes the Phosphorylation of VASP in HASM Cells
Because cAMP-mobilizing agents induce the activation of PKA and the inhibitory phosphorylation of VASP in different types of cells (9), we examined whether the b 2 AR agonists albuterol and formoterol modulate the PKA-dependent activity of VASP in HASM cells by using two different techniques, that is, immunoblot and immunocytochemical analyses with antibodies specifically recognizing VASP phosphorylated at Ser157, a major site of PKA phosphorylation.
As shown in Figure 1 , a 30-minute incubation with either albuterol or formoterol induced the dose-dependent phosphorylation of VASP, compared with diluent-treated cells at concentrations comparable to those for PGE2 ( Figures 1A and 1B , respectively). Notably, formoterol induced the phosphorylation of VASP at 10-100 times lower doses compared with albuterol, which is consistent with the systemic dose potency of formoterol, which is 10-100 times higher than that of albuterol (17) . Immunocytochemical analysis demonstrated that formoterol increased the phosphorylation of VASP at Ser157 in a concentrationdependent and time-dependent manner ( Figure E1 ). Similarly, lower doses of formoterol were required to inhibit the migration of HASM cells, compared with albuterol (the half maximal inhibitory concentration was approximately 0.1 mM and 1 mM for formoterol and albuterol, respectively) ( Figure E2 ), suggesting that a negative correlation exists between the phosphorylation levels of VASP and the migration of HASM cells.
Collectively, these data show that the b 2 AR agonists albuterol and formoterol induce the PKA-dependent phosphorylation of VASP at Ser157 in HASM cells, and inhibit the migration of HASM cells.
Binding with b 2 AR Is Required for the Albuterol-Dependent Phosphorylation of VASP and Inhibition of HASM Cell Migration
To determine whether binding with b 2 AR is required for the b 2 AR agonist-induced phosphorylation of VASP, we examined whether the nonselective b 2 AR inhibitor propranolol affects the albuterol-dependent phosphorylation of VASP. As shown in Figure 2 , cotreatment with propranolol markedly inhibited the albuterol-induced phosphorylation of VASP at Ser157, depending on the concentration of propranolol. In contrast, even the maximal concentration of propranolol exerted little effect on the PGE2-induced phosphorylation of VASP, demonstrating that propranolol specifically blocks the b 2 AR-dependent phosphorylation of VASP ( Figure 2 ).
Toconfirmour findings,weused(R)-albuteroland (S)-albuterol enantiomers, which possess differential affinity to b 2 AR. (R)-albuterol binds to b 2 AR with high affinity and promotes the formation of cAMP, whereas (S)-albuterol shows weak b 2 AR affinity (18) . We found that a 10-minute treatment with 0.05-50 mM (R)-albuterol markedly increased the phosphorylation of VASP at Ser157 in a concentration-dependent manner. In contrast, (S)-albuterol exerted little effect on the phosphorylation of VASP, and only high doses (50 mM) of (S)-albuterol induced a modest increase in VASP phosphorylation ( Figures 3A and 3B) . Immunocytochemical analysis also demonstrated that (R)-albuterol but not (S)-albuterol promoted the time-dependent phosphorylation of VASP in HASM cells ( Figure E3 ). Taken together, these data demonstrate that binding with b 2 AR is required for the albuterol-dependent phosphorylation of VASP at Ser157.
Because our previous study demonstrates that b 2 AR agonists inhibit the migration of HASM cells via an unknown mechanism (6), we examined whether the affinity of albuterol to b 2 AR is sufficient for the ability of albuterol to inhibit the migration of HASM cells. We found that (R)-albuterol, which demonstrates high affinity to b 2 AR (18) but not (S)-albuterol (which has weak b 2 AR binding properties) (18) , inhibited the basal or PDGFinduced migration of HASM cells ( Figure 3C ). These data suggest that binding with b 2 AR is required for the albuteroldependent inhibition of HASM cell migration.
PKA Modulates the Albuterol-Dependent Inhibition of HASM Cell Migration
Because PKA is a downstream effector of b 2 AR signaling, we next determined whether PKA is required for the albuteroldependent inhibition of HASM cell migration. We used HASM cells stably expressing green fluorescent protein (GFP)-tagged protein kinase inhibitor peptide (PKI-GFP) or the dominant negative mutant of regulatory PKA subunit (RevAB) (RevAB-GFP). HASM cells stably expressing GFP were used as a control. As we reported previously, both cell lines display a marked inhibition of PKA activity and phosphorylation of VASP at Ser157 (14) . As shown in Figure 4A , albuterol markedly inhibited the basal and platelet derived growth factor (PDGF)-induced migration of GFP-expressing cells. In contrast, albuterol exerted little effect on the migration of cells stably expressing PKI-GFP or RevAB-GFP ( Figure 4A ), demonstrating that PKA is required for the albuterol-dependent inhibition of HASM cell migration.
VASP Is Required for the cAMP-Dependent Inhibition of HASM Cell Migration
Because PKA inhibits VASP via phosphorylation at Ser157 in HASM cells (14), we next determined the role of VASP in the cAMP-dependent inhibition of HASM cell migration. We depleted endogenous VASP protein concentrations with a specific siRNA ( Figure 4B) , and examined the migration of HASM cell in the presence of a high dose (10 mM) of the potent cAMPmobilizing agent PGE2 (6) . As seen in Figure 4B , control siRNA GLO exerted little effect on both total VASP protein concentrations and the phosphorylation of VASP at Ser157 induced by PGE2. In contrast, siRNA VASP specifically attenuated total VASP concentrations, and completely suppressed the PGE2-dependent phosphorylation of VASP.
Consistent with our previous data (6), PGE2 markedly inhibited basal and PDGF-induced migration in control siRNAtransfected cells ( Figure 4C ). Importantly, siRNA VASP attenuated the PGE2-induced inhibition of basal and PDGF-induced HASM cell migration in a concentration-dependent manner (Figure 4C, gray bars) , suggesting that the phosphorylation of VASP is required for the cAMP-dependent inhibition of HASM cell migration.
Collectively, our data demonstrate that the albuterol-dependent inhibition of HASM cell migration is attributable to the b 2 ARdependent and PKA-dependent phosphorylation of VASP.
Prolonged Exposure to Albuterol Abolishes the b 2 AR Agonist-Dependent Phosphorylation of VASP
To determine whether prolonged treatment with b 2 AR agonists modulates the phosphorylation of VASP, we incubated growth-arrested HASM cells with albuterol or formoterol for up to 18 hours, followed by immunoblot analysis with phosphoSer157 VASP antibodies. As shown in Figure 5 , both albuterol and formoterol induced a transient increase in the phosphorylation of VASP that decreased by 3 hours of treatment.
To examine further the effects of prolonged exposure to b 2 AR agonists on the inhibition of VASP, HASM cells were preincubated with 3 mM albuterol or diluent for 24 hours and maintained for 2 hours in albuterol-free media, and then short-term treatment with albuterol was performed, followed by immunoblot analysis to detect the phosphorylation of VASP at Ser157 (see Figure E4 for a schematic representation). The dose and kinetics of b 2 AR tolerance were characterized as we previously described (19) . We found that 0.1-1 mM albuterol induced a marked phosphorylation of VASP at Ser157 in diluent-pretreated cells ( Figure  6A ), but failed to induce the phosphorylation of VASP at Ser157 in cells preincubated with albuterol for 24 hours ( Figure 6A) . Interestingly, the PGE2-dependent phosphorylation of VASP was not suppressed by preincubation with albuterol ( Figure  6A ), demonstrating that desensitization is attributable to alterations in the function of b 2 AR.
To determine the time required for the desensitization of b 2 AR, HASM cells were preincubated for 30-120 minutes with 1 mM albuterol, followed by the removal of albuterol and shortterm treatment with 1 mM albuterol (a schematic representation of this experiment is provided in Figure E5 ). As shown in Figure  6B , the level of desensitization was dependent on preincubation time. Preincubation with 1 mM albuterol for 30-120 minutes led to the time-dependent inhibition of VASP phosphorylation, and the suppression of VASP phosphorylation was detected after 120 minutes of preincubation ( Figure 6B ). Thus, prolonged incubation with albuterol inhibits the albuterol-dependent phosphorylation of VASP in a time-dependent and concentrationdependent manner, potentially because of alterations in the responsiveness of b 2 AR.
Chronic Exposure to Albuterol Abolishes Albuterol-Dependent and Formoterol-Dependent Inhibition of Migration of HASM Cells, and Further Increases Migratory Potential of HASM Cells
Because our data demonstrate that albuterol inhibits the migration of HASM cell attributable to the phosphorylation of VASP, Figure 4 . (A) The activation of protein kinase A (PKA) is required for the albuterol-dependent inhibition of HASM cell migration. HASM cells were stably transfected with green fluorescent protein (GFP)-tagged protein kinase inhibitor (PKI) peptide (PKI-GFP), the dominant negative mutant of regulatory PKA subunit (RevAB) (RevAB-GFP), or control GFP, and were serum-deprived for 48 hours, and then migration in the presence or absence of 10 mM albuterol and 10 ng/ml PDGF was examined. The migration of diluent-treated cells stably expressing GFP was taken as 1-fold. Data represent the mean values 6 SE of two independent experiments and three repetitions of each experiment, according to ANOVA (Bonferroni Dunn test). (B and C) Small interfering (si) RNA VASP suppresses the PGE2-dependent phosphorylation of VASP and attenuates the PGE2-induced inhibition of HASM cell migration. (B) HASM cells, transfected with 100 or 250 nM siRNA VASP, or control siGLO RISC-Free (GLO) siRNA, were growth-arrested and treated with 10 mM PGE2 or diluent for 30 minutes, and then immunoblot analysis with anti-phospho VASP Ser157 and anti-total VASP antibodies was performed. (C) Cells, transfected with 100 or 250 nM siRNA VASP or control siRNA, were subjected to a migration assay in Boyden chamber in the presence or absence of 10 mM PGE2 and 10 ng/ml PDGF. The data represent mean values 6 SE from three independent experiments. *P , 0.001 for control siRNA 1 PGE2 versus control siRNA. **P , 0.01 for siRNA VASP 1 PGE2 versus control siRNA 1 PGE2. All P values were determined according to ANOVA (Bonferroni-Dunn test).
we examined whether prolonged exposure to albuterol modulates the b 2 AR agonist-dependent inhibition of HASM cell migration. As shown in Figures 7A and 7B (solid bars) , albuterol, formoterol, and PGE2 significantly the inhibited basal and PDGF-induced migration of HASM cells preincubated with diluent. However, preincubation with 1 mM albuterol for 24 hours attenuated the inhibitory effects of albuterol and formoterol on the basal and PDGF-induced migration of HASM cells, compared with diluent-pretreated cells ( Figures 7A and 7B , gray bars). Importantly, pretreatment with albuterol exerted little effect on the ability of PGE2 to inhibit either the basal or PDGF-induced migration of HASM cells ( Figure 7B ), thus confirming our previous observation that chronic exposure to albuterol desensitizes cells at the b 2 AR level. Interestingly, chronic exposure to albuterol significantly promoted the PDGF-induced migration of HASM cells, compared with cells preincubated with diluent ( Figure 7B ). Collectively, these data demonstrate that the chronic exposure of HASM cells to albuterol specifically desensitizes cells to the inhibitory effects of b 2 -agonists on cell migration because of the suppression of b 2 AR-dependent VASP phosphorylation.
DISCUSSION
Anticapping VASP proteins play a critical role in actin cytoskeleton rearrangements during cell motility by directly modulating the formation of actin stress fibers at the leading edge of migrating cells. Our study shows that b 2 AR agonists inhibit the migration of HASM cells through the PKA-dependent phosphorylation of VASP. Importantly, prolonged exposure of HASM cells to the b 2 AR agonist albuterol prevented the b 2 AR-dependent phosphorylation of VASP as well as the inhibition of HASM cell migration, suggesting that albuterol-induced b 2 AR receptor tolerance abolishes the b 2 AR agonist-dependent inhibition of HASM cell migration through VASP.
Our data and those of others show that cAMP-mobilizing agents and glucocorticoids modulate the basal and mitogeninduced migration of HASM cells (5, 6) . We demonstrated that cAMP-inducing agents promote the depolymerization of actin in HASM cells (8) . PKA is activated by increases in cAMP concentrations, and inhibits the lysophosphatidic acid-induced migration of bovine ASM cells (7) . The molecular mechanisms regulating these effects, however, are not well understood. Evidence suggests that cAMP-inducing agents may modulate the actin cytoskeleton during cell motility through an activation of PKA, which regulates the activity of VASP by specific phosphorylation at Ser157. The PKA-dependent of VASP was demonstrated in rat aortic vascular smooth muscle cells (20) . The stimulation of human neutrophils by a chemoattractant induces the PKA-dependent phosphorylation of VASP at Ser157 (21) . VASP also plays a critical role in neuronal function by modulating the initiation of neurites and the outgrowth and guidance of axons (22) . The negative regulatory function of VASP phosphorylation in cell migration was also suggested (23) .
Here, we provide evidence linking the b 2 AR agonist-dependent phosphorylation of VASP to the inhibition of HASM cell migration induced by cAMP-mobilizing agents. Our data show that short-term treatment with b 2 AR agonists induces the b 2 ARdependent and PKA-dependent phosphorylation of VASP required for the b 2 AR agonist-induced inhibition of HASM cell migration.
Importantly, the stimulation of HASM cells with albuterol or formoterol induced a transient phosphorylation of VASP that was completely abolished after 3 hours of treatment with albuterol and 18 hours of treatment with formoterol. Because b 2 AR agonists are currently used as asthma therapeutics, we investigated whether HASM cells chronically treated with b 2 AR agonists will maintain their responsiveness to the albuterol-dependent and formoterol-dependent phosphorylation of VASP and their inhibition of cell migration. Interestingly, a previous report by Hastie and colleagues demonstrated a decreased phosphorylation of VASP in epithelial cells derived from patients with asthma who had been chronically treated with b 2 AR agonists (24) . We report that prolonged treatment with albuterol decreases the responsiveness of HASM cells to b 2 AR agonists. Thus, albuterol failed to induce the phosphorylation of VASP in HASM cells treated with albuterol for 24 hours. Further, preincubation with albuterol for 24 hours reversed the ability of albuterol and formoterol to inhibit the migration of HASM cells. Our data demonstrate that prolonged treatment with b 2 AR agonists desensitizes HASM to b 2 AR agonists, and suggest that the phosphorylation level of VASP may serve as a potential biomarker of airway responsiveness to b 2 AR agonists and b 2 AR HASM desensitization.
Interestingly, pretreatment with albuterol did not affect the inhibitory effects of PGE2 on the phosphorylation of VASP and of HASM cells, suggesting a differential mechanism of the level of receptor or downstream signaling. Our previously published studies demonstrated that PGE2 promotes the cAMP-dependent activation of PKA and phosphorylation of VASP in HASM cells via the prostaglandin E2 (EP2) receptor (25, 26) , which, in contrast to b 2 AR, is relatively resistant to agonist-specific desensitization. Indeed, the accumulation of cAMP and of PKA during both acute and chronic with agonists were markedly greater with PGE2 compared with b 2 AR agonists (14, (25) (26) (27) (28) with regard to greater efficiency in the inhibition of HASM cell growth (26, 29) and migration (6) . Indeed, our published data show that, in contrast to b 2 AR agonists that transiently increase the phosphorylation of VASP but decrease in effectiveness by 3 hours, PGE2 promotes a PKA-dependent phosphorylation of VASP that is sustained for up to 18 hours, suggesting that prolonged exposure to PGE2 does not desensitize EP2 receptors (25) . Such differences between b-agonists and PGE2 may be explained by differential mechanisms of b 2 AR and EP2 receptor desensitization in HASM cells. Our previous data demonstrate that, in HASM cells, the desensitization of the b 2 AR receptor is selectively mediated by G proteincoupled receptor kinases 2/3 (GRK2/3) that exert little effect on EP2 receptor functions (26) .
Our data demonstrate that the desensitization of VASP to b 2 AR agonists impairs the inhibitory effects of b 2 -agonists and promotes the migration of HASM cells. In terms of clinical significance, our findings suggest that the chronic use of b 2 -agonists could enhance the migration of ASM cells or prime them for an enhanced mitogenic response to growth factors. Ultimately, the enhanced migration of HASM cells and mitogenic responses may promote an asthma phenotype manifested by irreversible airflow obstruction. Although our data suggest that such mechanisms may be operative in chronic severe asthma, further clinical studies are needed to characterize the role of VASP definitively in the migration and proliferation of HASM cells in mediating the irreversible airflow obstruction of chronic asthma.
Understanding the cellular and molecular mechanisms of HASM remodeling is critically important, not only for advancing our knowledge of disease pathobiology, but also because such an understanding may lead to indentifying novel molecular targets for therapeutic intervention. This study identifies a mechanism of the inhibitory effects of b 2 AR agonists on the migration of HASM cells. We found that the b 2 AR agonist-induced activation of PKA modulates the phosphorylation of VASP that inhibits the migration of HASM cells. Furthermore, we found that the prolonged treatment of HASM with b 2 AR agonists desensitizes airways to further treatment with b 2 AR agonists. Our data suggest that a prolonged use of b 2 AR agonists in asthma as single therapy may promote the development of tolerance to b 2 AR agonists and the migration of ASM cells.
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